April 24, 2020 / 5:01 PM / in 3 months

BRIEF-Sumitovant Biopharma Reports Key Clinical And Regulatory Milestones By Myovant Sciences

April 24 (Reuters) - SUMITOVANT BIOPHARMA:

* SUMITOVANT BIOPHARMA - REPORTS KEY CLINICAL AND REGULATORY MILESTONES BY MYOVANT SCIENCES

* SUMITOVANT BIOPHARMA - MYOVANT SCIENCES SUBMITS NDA TO FDA FOR ONCE-DAILY, ORAL RELUGOLIX (120 MG) FOR TREATMENT OF MEN WITH ADVANCED PROSTATE CANCER

* SUMITOVANT BIOPHARMA - MYOVANT EXPECTS TO SUBMIT NDA FOR ONCE-DAILY RELUGOLIX COMBINATION THERAPY FOR TREATMENT OF WOMEN WITH UTERINE FIBROIDS IN MAY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below